Lyra posts slide deck with BEACON Phase 2 topline results for LYR-220 in CRS

Lyra Therapeutics, Inc.

LYR-220 evaluated in Phase 2 BEACON study for chronic rhinosinusitis with/without polyps in patients with prior ethmoidectomy.
Topline results posted as slide deck on Lyra investor website on Sept 12, 2023; no specific data included in this 8-K text.
Study identifier NCT05035654 on clinicaltrials.gov; two-part, patient-blinded, randomized trial.
No financial impact or guidance changes announced; materiality depends on the actual results not seen here.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.